Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. News
  7. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Delayed Xetra  -  11:35:59 2023-02-03 am EST
1.300 EUR   -1.89%
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
2022Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd
CI
2022Biofrontera AG Establishes UK Subsidiary to Strengthen Its Sales Activities in the Country
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

11/23/2022 | 05:41am EST

Biofrontera AG reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was EUR 6.83 million compared to EUR 5.38 million a year ago. Net loss was EUR 5.1 million compared to EUR 5.8 million a year ago. Basic loss per share from continuing operations was EUR 0.09 compared to EUR 0.1 a year ago. Diluted loss per share from continuing operations was EUR 0.08 compared to EUR 0.1 a year ago.
For the nine months, sales was EUR 21.91 million compared to EUR 18.47 million a year ago. Net loss was EUR 41.85 million compared to EUR 14.67 million a year ago. Basic loss per share from continuing operations was EUR 0.74 compared to EUR 0.26 a year ago. Diluted loss per share from continuing operations was EUR 0.66 compared to EUR 0.26 a year ago.


ę S&P Capital IQ 2022
All news about BIOFRONTERA AG
01/09Biofrontera Doses First Patient in Phase 3 Actinic Keratosis Clinical Trial
MT
2022Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd
CI
2022Biofrontera AG Establishes UK Subsidiary to Strengthen Its Sales Activities in the Coun..
CI
2022Biofrontera Ag Continues to Adhere to Forecast for Fiscal Year 2022
CI
2022Biofrontera AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sep..
CI
2022Earnings Flash (BFRI) BIOFRONTERA Reports Q3 Revenue $4.3M, vs. Street Est of $4.3M
MT
2022Biofrontera Says It Has Agreed to Buy Biofrontera AG Options
MT
2022BIOFRONTERA AG : RIGHTS ISSUE: 1 new share @ 1 EUR for 8 existing shares
FA
2022Biofrontera Appoints Fred Leffler as CFO
MT
2022Biofrontera Adopts Shareholder Rights Plan
MT
More news
Financials
Sales 2022 27,0 M 29,3 M 29,3 M
Net income 2022 -42,1 M -45,7 M -45,7 M
Net Debt 2022 - - -
P/E ratio 2022 -2,20x
Yield 2022 -
Capitalization 73,7 M 80,0 M 80,0 M
Capi. / Sales 2022 2,73x
Capi. / Sales 2023 2,16x
Nbr of Employees 102
Free-Float 49,7%
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,30 €
Average target price 2,80 €
Spread / Average Target 115%
EPS Revisions
Managers and Directors
Maria del Pilar de la Huerta Martinez Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA AG-14.75%80
JOHNSON & JOHNSON-6.82%430 370
ELI LILLY AND COMPANY-7.31%322 186
NOVO NORDISK A/S0.37%309 611
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-7.22%260 994